Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GONADOTROPIN-RELEASING HORMONE/LOW-DOSE STEROIDS NOT APPROPRIATE FOR STUDY IN BREAST CANCER HIGH RISKS -- FDA CMTE.; AGENCY WILL WORK TO REVISE PROTOCOL

Executive Summary

Gonadotropin-releasing hormone agonist (GnRHA) and a low-dose conjugated estrogens oral contraceptive should not move into larger clinical trials for women at high risk of breast cancer based on the results of a pilot study, FDA's Fertility & Maternal Health Advisory Committee concluded June 24.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel